⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937806 | 0.82 | KCNH2 (0.39) | — | |
| SCHEMBL3299995 | 0.82 | KCNH2 (0.50) | — | |
| SCHEMBL8739934 | 0.80 | PARP1 (0.46) | — | |
| SCHEMBL506617 | 0.78 | — | — | |
| SCHEMBL29561513 | 0.78 | — | — | |
| SCHEMBL906702 | 0.76 | — | — | |
| SCHEMBL378869 | 0.76 | — | — | |
| SCHEMBL243277 | 0.76 | — | — | |
| SCHEMBL13537005 | 0.76 | — | — | |
| SCHEMBL3671171 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633683-A1 | CYCLOOCTENE COMPOSITIONS AND USES THEREOF | Biogen MA Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024130105-A1 | CYCLOOCTENE COMPOSITIONS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3424936-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| WO-2019005297-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005297-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3094638-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| US-9738634-B2 | Heterocyclic amide compound and herbicide | SYNGENTA PARTICIPATIONS AG (CH) | 2017-08-22 | — | — | US | disclosed |
| EP-1919915-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| CN-101001846-A | Novel alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007021575-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021575-A2 | ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037817-A1 | Acetylenic piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| CN-1759120-A | Metal complexes | COVION ORGANIC SEMICONDUCTORS (DE) | 2006-04-12 | — | — | CN | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |